Table 2. Clinical characteristics of patients with hodgkin lymphoma and aplastic anemia.
| Patient | HL type Stage (if available) | HL Treatment pre-AA diagnosis | HL Status at AA diagnosis | Age at AA diagnosis/Sex | Interval between HL and AA diagnoses | AA treatment | Survival after AA diagnosis | Status of AA at last follow-up |
|---|---|---|---|---|---|---|---|---|
| Patients reported in this study | ||||||||
| UPENN 1 | N/A; Stage IIa |
ABVD, ASHAP | CR | 49/M | 14 years | hATG/CsA; Eltrombopag/Tac; Allo BMT | 12 months | Refractory; died of primary graft failure after Allo BMT |
| UPENN 2 | nodular sclerosis;Stage IV | None | Progression s/p 8 cycles Brentuximab | 31/M | ≤ 2 months; concurrent | Eltrombopag | 17 months | Refractory; died of AA complications |
| UPENN 3 | nodular sclerosis;Stage IVB | ABVD | CR | 46/M | 10 years | CsA/Solumedrol; hATG/G-CSF | 4 months | Refractory; transformed to TRMN |
| UPENN 4 | nodular sclerosis; Stage IVB | Noneb | CR s/p 6 cycles ABVD | 32/M | AA preceded HL by 13 years |
CsA/ATG | Not reached (>20 years) | CR s/p CsA |
| Patients from the Systematic Literature Review | ||||||||
| Brusamolino et al., 1994 | N/A | MOPP/ABVD | Presumed CR | N/A | N/A | Supportive | N/A | Died of hemorrhage |
| Johnston et al., 1991 | lymphocyte depleted; Stage IIIB | MOPP | CR | 31/F | 0 months; concurrent | Supportive | Not reached (34 months as of publication) | Active AA |
| Juliusson et al., 1991 | nodular sclerosis; Stage IIA | None | CR s/p Allo BMT | 46/M | 0 months; concurrent | Corticosteroids/ALG; Allo BMT | Not reached (16 months as of publication) | CR s/p Allo BMT |
| Louwagie et al., 1978 | lymphocyte predominant; Stage I | None | Concurrent | 24/M | ≤ 2 months; concurrent | Corticosteroids | 8 months | Died of cerebral hemorrhage |
| Mendenhall et al., 1989 | N/A; Stage IIIB | MOPP, MTNI | CR | 14/M | 2 years | Supportive | 1 months | Died within 1 month of AA diagnosis |
| Rovo et al., 2017 (5 cases) | 1 nodular sclerosis; 2 lymphocyte predominant; 1 mixed cellularity; 1 unspecified | Unknown | Unknown | Unknown | Concurrent; 12 months; 20 months; 8 years; 10 years | Unknown | Unknown | Unknown |
| Saitoh et al., 2007 | nodular sclerosis; Stage IVA | C-MOPP | CR | 39/F | 12 years | Prednisolone/CsA | 14 months | Refractory; died of GI hemorrhage |
| Zamar et al., 1956 | N/A | None | Concurrent | 12/M | 0 months; concurrent | Supportive | 3 months | Died 3 months after AA diagnosis |
N/A, Not Available; HL, Hodgkin Lymphoma; AA, Idiopathic Acquired Aplastic Anemia; ABVD, Doxorubicin, Bleomycin, Vinblastine, Dacarbazine; ASHAP, Doxorubicin, Solumedrol, Cytarabine, Cisplatin; MOPP, Mechlorethamine, Vincristine, Procarbazine, Prednisone; C-MOPP, Cyclophosphamide, Vincristine, Procarbazine, Prednisone; MTNI, Modified Total Nodal Irradiation; CR, Complete Remission; PR, Partial Response; Allo BMT, Allogenic Bone Marrow Transplant; ATG, Antithymocyte Globulin; hATG, Horse Antithymocyte Globulin; CsA, Cyclosporine A; Tac, Tacrolimus; G-CSF, Granulocyte Colony Stimulating Factor; ALG, Antilymphocyte Globulin; TRMN, Therapy-Related Myeloid Neoplasm; GI, Gastrointestinal.
aIncomplete staging information.
bAA diagnosed and treated before onset of HL.